Novo Nordisk Says Wegovy Improved Patients' Liver Disease [Yahoo! Finance]
Madrigal Pharmaceuticals, Inc. (MDGL)
Last madrigal pharmaceuticals, inc. earnings: 2/26 06:50 am
Check Earnings Report
US:NASDAQ Investor Relations:
madrigalpharma.com
Company Research
Source: Yahoo! Finance
Most Read from Bloomberg Is Denver's Big Bet on E-Bikes Paying Off? The Answer To Making Cities More Family-Friendly? Courtyards Chicago Mayor Seeks Property Tax Hike, Breaking Campaign Vow NY Transit Agency Takes Next Step on Brooklyn-Queens Rail Link Istanbul Tries Free Public Transit to Help Job Seekers The trial showed that semaglutide, the main ingredient in Novo's Wegovy, helped 37% of patients see an improvement in their liver fibrosis, while 62.9% achieved resolution of their liver disease, compared to patients receiving standard of care, the drugmaker said in a statement Friday. The results were the first part of an ongoing late stage trial in 1,200 adults with metabolic dysfunction-associated steatohepatitis, or MASH, and moderate-to-advanced liver fibrosis. Patients took the maximum dose of Wegovy. Novo said it expects to file for regulatory approval in the first half of 2025. The Danish pharmaceutical company will also present further details of the result
Show less
Read more
Impact Snapshot
Event Time:
MDGL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MDGL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MDGL alerts
High impacting Madrigal Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
MDGL
News
- Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on February 26, 2025GlobeNewswire
- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) had its price target raised by analysts at HC Wainwright from $390.00 to $400.00. They now have a "buy" rating on the stock.MarketBeat
- Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on Rezdiffra [Yahoo! Finance]Yahoo! Finance
- Why Madrigal Pharmaceuticals Stock Is Sinking Today [Yahoo! Finance]Yahoo! Finance
- Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on RezdiffraGlobeNewswire